Skip to main
VCEL

Vericel (VCEL) Stock Forecast & Price Target

Vericel (VCEL) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Vericel Corporation is expected to experience significant revenue growth driven by its MACI product, with projections indicating a high-teens annual growth rate due to both an increase in volumes and annual average selling price (ASP) improvements. The company has demonstrated a robust growth trajectory, anticipating approximately 21.2% year-over-year growth in MACI revenues for fiscal year 2026, supported by a strong conversion rate of biopsies to MACI. Additionally, the fourth quarter is projected to show a notable 26% quarter-over-quarter revenue increase, indicating a solid performance outlook for the company.

Bears say

Vericel Corp's financial outlook is negatively impacted by a downward revision of projected MACI revenues for FY26 and FY27, indicating a decrease of approximately 200 basis points. The company faces several risks affecting its revenue, including slower adoption of MACI and MACI Arthro by physicians, sluggish sales in the burn care segment, and potential disruptions related to the expansion of its sales force. Moreover, any failure to meet top-line expectations in a quarter could result in the stock trading at historical low valuation levels, further reflecting the company's challenging position in the market.

Vericel (VCEL) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Vericel and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Vericel (VCEL) Forecast

Analysts have given Vericel (VCEL) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Vericel (VCEL) has a Strong Buy consensus rating as of Feb 19, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $57.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $57.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Vericel (VCEL)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.